Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
Condition(s):Relapsed Refractory Multiple MyelomaLast Updated:January 16, 2024Suspended
Hide Studies Not Open or Pending
Condition(s):Relapsed Refractory Multiple MyelomaLast Updated:January 16, 2024Suspended
Condition(s):Relapsed Multiple Myeloma; Relapsed-Refractory Multiple MyelomaLast Updated:June 8, 2023Terminated
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:May 4, 2022Withdrawn
Condition(s):Relapsed/Refractory B-cell Non-Hodgkin’s LymphomaLast Updated:February 9, 2023Unknown status
Condition(s):Multiple MyelomaLast Updated:November 18, 2019Completed
Condition(s):Relapsed and/or Relapsed-refractory Multiple MyelomaLast Updated:October 23, 2020Terminated
Condition(s):Mantle Cell LymphomaLast Updated:December 19, 2023Recruiting
Condition(s):NeuroblastomaLast Updated:October 16, 2023Active, not recruiting
Condition(s):Diffuse Large B-cell Lymphoma; Rituximab; ToripalimabLast Updated:June 16, 2020Unknown status
Condition(s):Hematological MalignancyLast Updated:February 2, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.